• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国武汉 COVID-19 患者出院 3 年后的健康结局:一项队列研究。

Health outcomes of COVID-19 patients from Wuhan, China 3-year after hospital discharge: a cohort study.

机构信息

Department of Anesthesiology, Daping Hospital, Army Medical University, Chongqing, People's Republic of China.

Department of Respiratory Medicine, Daping Hospital,Army Medical University, Chongqing, People's Republic of China.

出版信息

BMJ Open. 2024 Aug 17;14(8):e084770. doi: 10.1136/bmjopen-2024-084770.

DOI:10.1136/bmjopen-2024-084770
PMID:39153784
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11331845/
Abstract

OBJECTIVES

To evaluate changes in health outcomes between years 2 and 3 after discharge following COVID-19 and to identify risk factors for poor health 3-year post-discharge.

DESIGN

This is a multicentre observational cohort study.

SETTING

This study was conducted in two centres from Wuhan, China.

PARTICIPANTS

Eligibility screening has been performed in 3988 discharged laboratory-confirmed adult COVID-19 patients. Exclusion criteria were refusal to participate, inability to contact and death before follow-up. The WHO COVID-19 guidelines on defining disease severity were adopted.

RESULTS

1594 patients participated in the 1-year, 2-year and 3-year follow-ups, including 796 (49.9%) male patients, and 422 (26.5%) patients were classified in the severe disease group. 3 years after discharge, 182 (11.4%) patients still complained of at least one symptom. The most common symptoms were fatigue, myalgia, chest tightness, cough, anxiety, shortness of breath and expectoration. Fatigue or myalgia, the most common symptom cluster, frequently coexisted with chest symptoms and anxiety. Symptom persistence between years 2 and 3 was reported in 70 patients (4.4%) for which intensive care unit (ICU) admission was a risk factor (p=0.038). Of the 1586 patients who completed the chronic obstructive pulmonary disease assessment test (CAT), 97 (6.1%) scored ≥10, with older age being associated with CAT ≥10 (p=0.007).

CONCLUSIONS

Between years 2 and 3 after SARS-CoV-2 infection, most patients returned to an asymptomatic state, and only a few were still symptomatic. ICU admission was a risk factor for symptom persistence.

摘要

目的

评估 COVID-19 出院后 2 至 3 年的健康结果变化,并确定出院后 3 年健康状况不佳的危险因素。

设计

这是一项多中心观察性队列研究。

地点

本研究在中国武汉的两个中心进行。

参与者

对 3988 名已出院的实验室确诊成人 COVID-19 患者进行了资格筛选。排除标准为拒绝参与、无法联系和随访前死亡。采用了世界卫生组织 COVID-19 关于定义疾病严重程度的指南。

结果

1594 名患者参加了 1 年、2 年和 3 年的随访,包括 796 名(49.9%)男性患者,422 名(26.5%)患者被归类为重症组。出院 3 年后,仍有 182 名(11.4%)患者至少有一个症状。最常见的症状是疲劳、肌肉疼痛、胸闷、咳嗽、焦虑、呼吸急促和咳痰。最常见的症状群疲劳或肌肉疼痛,常伴有胸部症状和焦虑。70 名患者(4.4%)报告在 2 年至 3 年之间持续存在症状,入住重症监护病房(ICU)是一个危险因素(p=0.038)。在完成慢性阻塞性肺疾病评估测试(CAT)的 1586 名患者中,有 97 名(6.1%)得分≥10,年龄较大与 CAT≥10 相关(p=0.007)。

结论

在 SARS-CoV-2 感染后 2 至 3 年内,大多数患者恢复到无症状状态,只有少数患者仍有症状。入住 ICU 是症状持续存在的危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baf1/11331845/6c0e1898175c/bmjopen-14-8-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baf1/11331845/67fb496a55d9/bmjopen-14-8-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baf1/11331845/5dd35ba97241/bmjopen-14-8-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baf1/11331845/6c0e1898175c/bmjopen-14-8-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baf1/11331845/67fb496a55d9/bmjopen-14-8-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baf1/11331845/5dd35ba97241/bmjopen-14-8-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baf1/11331845/6c0e1898175c/bmjopen-14-8-g003.jpg

相似文献

1
Health outcomes of COVID-19 patients from Wuhan, China 3-year after hospital discharge: a cohort study.中国武汉 COVID-19 患者出院 3 年后的健康结局:一项队列研究。
BMJ Open. 2024 Aug 17;14(8):e084770. doi: 10.1136/bmjopen-2024-084770.
2
Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, China.COVID-19 感染出院 1 年后幸存者的症状和健康结局:中国武汉医院的报告。
JAMA Netw Open. 2021 Sep 1;4(9):e2127403. doi: 10.1001/jamanetworkopen.2021.27403.
3
Two-Year Health Outcomes in Hospitalized COVID-19 Survivors in China.中国住院 COVID-19 幸存者的两年健康结局。
JAMA Netw Open. 2022 Sep 1;5(9):e2231790. doi: 10.1001/jamanetworkopen.2022.31790.
4
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.新冠肺炎出院患者 6 个月的后果:一项队列研究。
Lancet. 2021 Jan 16;397(10270):220-232. doi: 10.1016/S0140-6736(20)32656-8. Epub 2021 Jan 8.
5
Post-sequelae one year after hospital discharge among older COVID-19 patients: A multi-center prospective cohort study.新冠肺炎出院一年后老年患者的后遗症:一项多中心前瞻性队列研究。
J Infect. 2022 Feb;84(2):179-186. doi: 10.1016/j.jinf.2021.12.005. Epub 2021 Dec 10.
6
3-year outcomes of discharged survivors of COVID-19 following the SARS-CoV-2 omicron (B.1.1.529) wave in 2022 in China: a longitudinal cohort study.2022 年中国 SARS-CoV-2 奥密克戎(B.1.1.529)波后出院的 COVID-19 幸存者的 3 年结局:一项纵向队列研究。
Lancet Respir Med. 2024 Jan;12(1):55-66. doi: 10.1016/S2213-2600(23)00387-9. Epub 2023 Nov 21.
7
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.新冠肺炎患者出院后 6 个月的后果:一项队列研究。
Lancet. 2023 Jun 17;401(10393):e21-e33. doi: 10.1016/S0140-6736(23)00810-3. Epub 2023 Jun 12.
8
Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy.意大利伦巴第地区重症监护病房中 COVID-19 患者死亡的相关危险因素。
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355. doi: 10.1001/jamainternmed.2020.3539.
9
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.一项针对高风险确诊严重 SARS-CoV-2 疾病患者的随机开放标签 II 期临床试验,比较 SARS-CoV-2 感染后恢复期患者输注血浆与未输注血浆的疗效(RECOVER):一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Oct 6;21(1):828. doi: 10.1186/s13063-020-04735-y.
10
Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China.中国全国范围内的分析:湖北省(疫情中心)和湖北省外(非疫情中心)住院治疗的 COVID-19 患者的临床特征和结局。
Eur Respir J. 2020 Jun 4;55(6). doi: 10.1183/13993003.00562-2020. Print 2020 Jun.

引用本文的文献

1
Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of Symptoms 3 Years Post-SARS-CoV-2 Infection.新冠病毒病的长期后遗症:对感染严重急性呼吸综合征冠状病毒2三年后症状的系统评价和荟萃分析
J Med Virol. 2025 Jun;97(6):e70429. doi: 10.1002/jmv.70429.

本文引用的文献

1
SARS-CoV-2 post-acute sequelae in previously hospitalised patients: systematic literature review and meta-analysis.SARS-CoV-2 后急性后遗症在既往住院患者中的研究:系统文献回顾和荟萃分析。
Eur Respir Rev. 2023 Jul 12;32(169). doi: 10.1183/16000617.0254-2022. Print 2023 Sep 30.
2
A systematic review and meta-analysis of long-term sequelae of COVID-19 2-year after SARS-CoV-2 infection: A call to action for neurological, physical, and psychological sciences.一项关于 SARS-CoV-2 感染 2 年后 COVID-19 长期后遗症的系统回顾和荟萃分析:呼吁神经科学、物理学和心理学界采取行动。
J Med Virol. 2023 Jun;95(6):e28852. doi: 10.1002/jmv.28852.
3
Symptom Burden among Older COVID-19 Survivors Two Years after Hospital Discharge.
新冠病毒感染幸存者出院两年后的症状负担
Aging Dis. 2023 Dec 1;14(6):2238-2248. doi: 10.14336/AD.2023.0304.
4
Post-COVID health-related quality of life and somatic symptoms: A national survey in Japan.新冠后健康相关生命质量和躯体症状:日本的一项全国性调查。
Am J Med Sci. 2023 Aug;366(2):114-123. doi: 10.1016/j.amjms.2023.04.018. Epub 2023 Apr 28.
5
Fatigue, sleepiness and sleep quality are SARS-CoV-2 variant independent in patients with long COVID symptoms.疲劳、嗜睡和睡眠质量与长新冠症状患者的 SARS-CoV-2 变异株无关。
Inflammopharmacology. 2023 Dec;31(6):2819-2825. doi: 10.1007/s10787-023-01190-4. Epub 2023 Apr 5.
6
Long COVID: major findings, mechanisms and recommendations.长新冠:主要发现、机制和建议。
Nat Rev Microbiol. 2023 Mar;21(3):133-146. doi: 10.1038/s41579-022-00846-2. Epub 2023 Jan 13.
7
Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies.全球新兴的 SARS-CoV-2 奥密克戎变异株:影响、挑战与策略。
J Infect Public Health. 2023 Jan;16(1):4-14. doi: 10.1016/j.jiph.2022.11.024. Epub 2022 Nov 19.
8
Two-Year Health Outcomes in Hospitalized COVID-19 Survivors in China.中国住院 COVID-19 幸存者的两年健康结局。
JAMA Netw Open. 2022 Sep 1;5(9):e2231790. doi: 10.1001/jamanetworkopen.2022.31790.
9
Long COVID: which symptoms can be attributed to SARS-CoV-2 infection?长期新冠:哪些症状可归因于SARS-CoV-2感染?
Lancet. 2022 Aug 6;400(10350):411-413. doi: 10.1016/S0140-6736(22)01385-X.
10
Symptoms and risk factors for long COVID in non-hospitalized adults.非住院成年人的长新冠症状和风险因素。
Nat Med. 2022 Aug;28(8):1706-1714. doi: 10.1038/s41591-022-01909-w. Epub 2022 Jul 25.